Your SlideShare is downloading. ×
0
US Drug for Prophylactic Human Papillomavirus Vaccines - Market Analysis to 2022
US Drug for Prophylactic Human Papillomavirus Vaccines - Market Analysis to 2022
US Drug for Prophylactic Human Papillomavirus Vaccines - Market Analysis to 2022
US Drug for Prophylactic Human Papillomavirus Vaccines - Market Analysis to 2022
US Drug for Prophylactic Human Papillomavirus Vaccines - Market Analysis to 2022
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

US Drug for Prophylactic Human Papillomavirus Vaccines - Market Analysis to 2022

4

Published on

Complete report is available @ http://www.reportsnreports.com/reports/291517-pharmapoint-prophylactic-human-papillomavirus-vaccines-us-drug-forecast-and-market-analysis-to-2022.html . …

Complete report is available @ http://www.reportsnreports.com/reports/291517-pharmapoint-prophylactic-human-papillomavirus-vaccines-us-drug-forecast-and-market-analysis-to-2022.html .
In the US the total number of HPV vaccine doses delivered annually is likely to grow steadily over the next few years, as more males receive vaccination and Merck's nine-valent vaccine V503 becomes available in 2015. US market growth will contribute to global growth in the HPV vaccines sector. There is no indication that coverage rates for adolescent girls will increase dramatically over the forecast period, as they have been relatively stable over the past few years. However, a modest increase will likely be achieved following the introduction of V503, which will be accompanied by a marketing and awareness campaign.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
4
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022 Published: Mar 2014 Single User PDF: US$ 4995 Corporate User PDF: US$ 14985 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 1© ReportsnReports.com / Contact sales@reportsandreports.com
  • 2. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022 The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector. In the US the total number of HPV vaccine doses delivered annually is likely to grow steadily over the next few years, as more males receive vaccination and Merck's nine- valent vaccine V503 becomes available in 2015. US market growth will contribute to global growth in the HPV vaccines sector. Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 2© ReportsnReports.com / Contact sales@reportsandreports.com
  • 3. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022 Scope Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in the US from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting the US Prophylactic Human Papillomavirus Vaccines disease market. Request a sample of this report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=291517 . Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 3© ReportsnReports.com / Contact sales@reportsandreports.com
  • 4. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022 Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in the US Complete report is available @ http://www.reportsnreports.com/reports/291517- pharmapoint-prophylactic-human-papillomavirus-vaccines-us-drug-forecast-and- market-analysis-to-2022.html . Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 4© ReportsnReports.com / Contact sales@reportsandreports.com
  • 5. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022 Table of Contents 1 Table of Contents 4 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 9 2.1 Catalyst 9 2.2 Related Reports 9 2.3 Upcoming Related Reports 11 3 Disease Overview 12 3.1 Etiology and Pathophysiology 12 3.1.1 Etiology 12 3.1.2 Pathophysiology 13 3.2 Symptoms 15 Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=291517 . Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 5© ReportsnReports.com / Contact sales@reportsandreports.com

×